GlassScriptPhysician profile
Clare Allen Ross
NPI 1518959261
$4,618.74
in general payments reported to CMS, 2019-2025
26 companies · $900 in 2025
The $900 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $747 · 2023: $1,003 · 2024: $1,583 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414 · Education: $71.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,414.16 |
| Education | $71.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $535.58 | 2021-2025 | Camzyos, Eliquis |
| Amgen INC. | $503.43 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $489.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $484.61 | 2021-2025 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $435.96 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.82 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $361.31 | 2022-2025 | Lifevest |
| Scpharmaceuticals INC. | $302.08 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $251.59 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $142.78 | 2022-2025 | Verquvo |
| Medtronic, INC. | $125.11 | 2024 | Selectsecure |
| Lexicon Pharmaceuticals, INC. | $108.97 | 2023-2024 | Inpefa |
| Abbott Laboratories | $101.27 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Novo Nordisk INC | $85.44 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $69.25 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $40.57 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $32.30 | 2024 | Zio Monitor, Zio Xt Patch |
| Lilly USA, LLC | $21.74 | 2025 | Zepbound, Mounjaro |
| Kestra Medical Technology Services, INC. | $21.02 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $20.41 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $19.87 | 2022 | |
| Bridgebio Pharma, INC. | $17.32 | 2025 | Attruby |
| Tactile Systems Technology INC | $16.72 | 2025 | Nimbl, Flexitouch Plus |
| Alnylam Pharmaceuticals INC. | $16.37 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $15.34 | 2025 | Evkeeza |
| Heartflow, INC. | $14.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clare Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.